Supplementary Material

# Supplementary Reference Tables

|  |
| --- |
| **Supplemental Table 1.** Cancer and ICI electronic health record data definitions |
| **Cancer/Immunotherapy** | **Codes** |
| Melanoma | ICD-9-CM: 172ICD-10-CM: C43 |
| Renal cell carcinoma | ICD-9-CM: 189ICD-10-CM: C64 |
| Lung cancer | ICD-9-CM: 162ICD-10-CM: C34 |
| Urothelial cancer | ICD-9-CM: 188ICD-10-CM: C67 |
| Head and neck cancer | ICD-9-CM: 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 160, 161ICD-10-CM: C00, C01, C02, C03, C04, C05, C06, C07, C08, C09, C10, C11, C12, C13, C14 |
| Gastric cancer | ICD-9-CM: 151ICD-10-CM: C16 |
| Colon cancer | ICD-9-CM: 153ICD-10-CM: C18 |
| Liver cancer | ICD-9-CM: 155ICD-10-CM: C22 |
| Cervical cancer | ICD-9-CM: 180ICD-10-CM: C53 |
| Endometrial cancer | ICD-9-CM: 179, 182ICD-10-CM: C54, C55 |
| Breast cancer | ICD-9-CM: 174, 175ICD-10-CM: C50 |
| Hodgkins disease | ICD-9-CM: 201ICD-10-CM: C81 |
| Merkel cell carcinoma | ICD-9-CM: ‘209.31’, ‘209.32’, ‘209.33’, ‘209.34’, ‘209.35’, ‘209.36’ICD-10-CM: C4A |
| Rectal cancer | ICD-9-CM: 154.1ICD-10-CM: C20 |
| Prostate cancer | ICD-9-CM: 185ICD-10-CM: C61 |
| Esophageal cancer | ICD-9-CM: 150ICD-10-CM: C15 |
| Leukemia | ICD-9-CM: 204, 205, 206, 207, 208ICD-10-CM: C91, C92, C93, C94, C95 |
| Other lymphoma | ICD-9-CM: 200, 202ICD-10-CM: C82, C83, C84, C85, C86, C88 |
| Other cancer | ICD-9-CM: 195ICD-10-CM: C76 |
| Pembrolizumab | Regex: 'pembrolizumab', 'keytruda' |
| Nivolumab | Regex: 'nivolumab', 'opdivo' |
| Cemiplimab | Regex: 'cemiplimab', 'libtayo' |
| Avelumab | Regex: 'avelumab', 'bavencio' |
| Durvalumab | Regex: 'durvalumab', 'imfinzi' |
| Atezolizumab | Regex: 'atezolizumab', 'tecentriq' |
| Ipilimumab | Regex: 'ipilumumab', 'yervoy' |
| Tremilumumab | Regex: 'tremilumumab' |

|  |
| --- |
| **Supplemental Table 2.** Autoimmune disease electronic health record definitions |
| **Autoimmune Disease** | **Codes** |
| Endocrine: Hashimoto's thyroiditis | ICD-9-CM: 245ICD-10-CM: E06.3 |
| Endocrine: T1D | ICD-9-CM: 250.01, 250.03, 250.11, 250.13, 250.21, 250.23, 250.31, 250.33, 250.41, 250.43, 250.51, 250.53, 250.61, 250.63, 250.71, 250.73, 250.81, 250.83, 250.91, 250.93ICD-10-CM: E10 |
| GI: Autoimmune hepatitis | ICD-9-CM: 571.42ICD-10-CM: K75.4 |
| GI: Crohn's disease | ICD-10-CM: K50 |
| GI: Primary biliary cholangitis (PBC) | ICD-10-CM: K74.3, K74.5 |
| GI: Ulcerative colitis (UC) | ICD-9-CM: 556ICD-10-CM: K51 |
| Neuro: Guillain-Barre Syndrome | ICD-10-CM: G61.0 |
| Neuro: Lambert-Eaton syndrome | ICD-9-CM: 358.3ICD-10-CM: G70.8, G73.1 |
| Neuro: Multiple sclerosis | ICD-9-CM: 340ICD-10-CM: G35 |
| Neuro: Myasthenia gravis | ICD-9-CM: 358.0, 775.2ICD-10-CM: G70.0 |
| Neuro: Myelitis transversa | ICD-9-CM: 341.2ICD-10-CM: G37.3 |
| Skin: Dermatitis herpetiformis | ICD-9-CM: 694.0, 694.2ICD-10-CM: L13.0 |
| Skin: Pemphigoid | ICD-9-CM: 694.5, 694.6ICD-10-CM: L12 |
| Skin: Pemphigus | ICD-9-CM: 694.4ICD-10-CM: L10 |
| Skin: Psoriasis | ICD-9-CM: 696.1, 696.2, 696.8ICD-10-CM: L40, L41 |
| Skin: Pyoderma | ICD-9-CM: 686.0ICD-10-CM: L08.0, L88 |
| Skin: Vitiligo | ICD-9-CM: 709.1ICD-10-CM: L80, H02.73 |

# Supplementary Methods

## Manual chart review process

Clinical notes were filtered for history and physical examination (H&P) and progress notes occurring on or after immune checkpoint inhibitor (ICI) therapy initiation. All H&P and progress notes were reviewed looking for the indicated immune-related adverse events (irAE), focusing on the assessment and plan sections. Common keywords for each irAE are listed. IrAE was classified if the oncologist or relevant specialist noted suspicion that the presentation was secondary to ICI therapy. This chart review pipeline was developed by SDT with guidance by CG, JL, AK, and JS. SDT trained GMP, KJR, CDM, JDJ, JT, KV, PD, SM, UR for chart review with this guide. SDT additionally reviewed 50 random charts from the other reviewers to compare agreement of the irAEs found – this resulted in greater than 90% agreement.

|  |
| --- |
| **Supplemental Table 3.** IrAE chart review clinical note specialties and keywords. |
| irAE | Specialty | Keywords |
| Cutaneous | Oncology, Dermatology | rash, pruritis, Vitiligo, Stevens-Johnson syndrome (SJS), Toxic epidermal necrolysis (TEN) |
| Thyroid dysfunction | Oncology, Endocrinology | abnormal TSH, thyroiditis, hypothyroidism, thyroid dysfunction |
| Hypophysitis/adrenal insufficiency | Oncology, Endocrinology | hypophysitis, adrenal insufficiency, abnormal ACTH, abnormal cortisol |
| Diabetes | Oncology, Endocrinology | diabetes, ketoacidosis, abnormal A1C, abnormal glucose |
| Diarrhea/Constipation | Oncology, Gastroenterology | diarrhea, constipation, abnormal bowel movements |
| Colitis | Oncology, Gastroenterology | colitis, GI related ED visit, abnormal bowel movements |
| Hepatic | Oncology, Hepatology | hepatitis, cholangitis, transaminitis |
| Pneumonitis | Oncology, Pulmonology | pneumonitis, pneumonia (confirm if this is referring to pneumonitis), pulmonary related ED visit |
| Cardiac | Oncology, Cardiology | myocarditis, pericarditis, myopericarditis |
| Encephalitis | Oncology, Neurology | encephalitis |